Imagion Biosystems has announced a notification to ineligible shareholders regarding the renounceable pro-rata offer of 28 October 2019.
Read the notification.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer